GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » PB Ratio

ABEO (Abeona Therapeutics) PB Ratio : 5.60 (As of Dec. 12, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Abeona Therapeutics's share price is $5.91. Abeona Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $1.06. Hence, Abeona Therapeutics's PB Ratio of today is 5.60.

The historical rank and industry rank for Abeona Therapeutics's PB Ratio or its related term are showing as below:

ABEO' s PB Ratio Range Over the Past 10 Years
Min: 0.37   Med: 2.09   Max: 55.46
Current: 5.58

During the past 13 years, Abeona Therapeutics's highest PB Ratio was 55.46. The lowest was 0.37. And the median was 2.09.

ABEO's PB Ratio is ranked worse than
78.19% of 1279 companies
in the Biotechnology industry
Industry Median: 2.52 vs ABEO: 5.58

During the past 12 months, Abeona Therapeutics's average Book Value Per Share Growth Rate was 18.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -72.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -64.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Abeona Therapeutics was 146.80% per year. The lowest was -72.40% per year. And the median was -4.60% per year.

Back to Basics: PB Ratio


Abeona Therapeutics PB Ratio Historical Data

The historical data trend for Abeona Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics PB Ratio Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.53 1.47 1.17 2.04 8.96

Abeona Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.72 8.96 - 2.41 5.99

Competitive Comparison of Abeona Therapeutics's PB Ratio

For the Biotechnology subindustry, Abeona Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's PB Ratio falls into.



Abeona Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Abeona Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=5.91/1.055
=5.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Abeona Therapeutics  (NAS:ABEO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Abeona Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics Business Description

Traded in Other Exchanges
Address
6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
Executives
Mark Alvino director C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Christine Berni Silverstein officer: Chief Financial Officer C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Leila Alland director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Brendan M. O'malley officer: SVP, General Counsel 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Vishwas Seshadri director, officer: Chief Executive Officer 64 STRYKER COURT, BRIDGEWATER NJ 08807
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Michael Amoroso officer: Chief Operating Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr officer: Vice President, Controller 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219